NBW Capital LLC acquired a new position in Pfizer Inc. (NYSE:PFE) during the 4th quarter, according to the company in its most recent Form 13F filing with the Securities & Exchange Commission. The institutional investor acquired 8,710 shares of the biopharmaceutical company’s stock, valued at approximately $321,000.
A number of other large investors have also recently made changes to their positions in the stock. Marietta Wealth Management LLC boosted its position in Pfizer by 5.5% during the 4th quarter. Marietta Wealth Management LLC now owns 60,568 shares of the biopharmaceutical company’s stock valued at $2,230,000 after acquiring an additional 3,164 shares in the last quarter. Swedbank lifted its holdings in shares of Pfizer by 15.0% during the 4th quarter. Swedbank now owns 4,325,914 shares of the biopharmaceutical company’s stock valued at $158,934,000 after purchasing an additional 565,427 shares during the last quarter. Blair William & Co. IL lifted its holdings in shares of Pfizer by 6.9% during the 4th quarter. Blair William & Co. IL now owns 1,181,546 shares of the biopharmaceutical company’s stock valued at $43,493,000 after purchasing an additional 76,683 shares during the last quarter. OmniStar Financial Group Inc. lifted its holdings in shares of Pfizer by 12.6% during the 4th quarter. OmniStar Financial Group Inc. now owns 22,935 shares of the biopharmaceutical company’s stock valued at $844,000 after purchasing an additional 2,560 shares during the last quarter. Finally, CI Investments Inc. lifted its holdings in shares of Pfizer by 24.8% during the 4th quarter. CI Investments Inc. now owns 981,742 shares of the biopharmaceutical company’s stock valued at $36,138,000 after purchasing an additional 194,976 shares during the last quarter. 67.36% of the stock is currently owned by institutional investors.
PFE stock traded down $0.57 during mid-day trading on Tuesday, hitting $33.69. 549,432 shares of the company were exchanged, compared to its average volume of 35,504,273. The company has a market capitalization of $187.26 billion, a PE ratio of 22.10, a price-to-earnings-growth ratio of 2.79 and a beta of 0.70. The company has a current ratio of 1.40, a quick ratio of 1.13 and a debt-to-equity ratio of 0.76. Pfizer Inc. has a twelve month low of $27.88 and a twelve month high of $43.08. The firm has a fifty day simple moving average of $35.94 and a 200 day simple moving average of $37.10.
Pfizer (NYSE:PFE) last announced its quarterly earnings data on Tuesday, February 2nd. The biopharmaceutical company reported $0.42 earnings per share for the quarter, missing the Thomson Reuters’ consensus estimate of $0.46 by ($0.04). The company had revenue of $11.68 billion for the quarter, compared to analyst estimates of $11.32 billion. Pfizer had a return on equity of 24.88% and a net margin of 17.85%. Pfizer’s revenue was up 11.8% on a year-over-year basis. During the same period in the prior year, the business earned $0.55 earnings per share. As a group, sell-side analysts anticipate that Pfizer Inc. will post 2.89 earnings per share for the current year.
The firm also recently declared a quarterly dividend, which will be paid on Friday, March 5th. Stockholders of record on Friday, January 29th will be issued a $0.39 dividend. The ex-dividend date is Thursday, January 28th. This is a positive change from Pfizer’s previous quarterly dividend of $0.38. This represents a $1.56 annualized dividend and a dividend yield of 4.63%. Pfizer’s payout ratio is 52.88%.
PFE has been the subject of a number of research analyst reports. Sanford C. Bernstein assumed coverage on Pfizer in a research note on Tuesday, November 10th. They issued a “market perform” rating and a $42.00 target price for the company. Mizuho lowered their target price on Pfizer from $44.00 to $42.00 and set a “buy” rating on the stock in a report on Wednesday, February 3rd. JPMorgan Chase & Co. set a $36.00 price target on shares of Pfizer and gave the company a “neutral” rating in a research report on Wednesday, February 3rd. The Goldman Sachs Group set a $40.00 target price on Pfizer and gave the company a “neutral” rating in a research report on Thursday, January 21st. Finally, DZ Bank restated a “buy” rating and issued a $41.00 price target on shares of Pfizer in a research note on Wednesday, February 3rd. Eleven analysts have rated the stock with a hold rating and five have issued a buy rating to the company. Pfizer has an average rating of “Hold” and a consensus price target of $39.38.
Pfizer Inc develops, manufactures, and sells healthcare products worldwide. It offers medicines and vaccines in various therapeutic areas, including cardiovascular metabolic and pain under the Eliquis, Chantix/Champix, and Premarin family brands; biologics, small molecules, immunotherapies, and biosimilars under the Ibrance, Sutent, Xtandi, Xalkori, Inlyta, Braftovi + Mektovi brands; and sterile injectable and anti-infective medicines under the Sulperazon, Medrol, Vfend, and Zithromax brands.
Featured Article: How big is the FinTech market?
Want to see what other hedge funds are holding PFE? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Pfizer Inc. (NYSE:PFE).
Receive News & Ratings for Pfizer Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Pfizer and related companies with MarketBeat.com's FREE daily email newsletter.